Ghost Tree Capital, LLC
- SEC CIK
- 0001595851
- Latest filing
- Nov 14, 2024
Holdings in Q2 2024
Holdings as of Jun 30, 2024, filed Aug 14, 2024. Long positions only; changes compare share counts with Q1 2024.
- Positions
- 59
- −6 vs. Q1 2024
- Portfolio value
- $287.4M
- −$23.7M (−7.6%) vs. Q1 2024
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| BHVNBiohaven Ltd. | COM | 490,000 | $17.0M | 5.9% | +205,000+71.9% | Added | History |
| MLTXMoonLake Immunotherapeutics | CLASS A ORD | 300,000 | $13.2M | 4.6% | 00.0% | Unchanged | History |
| SLNOSoleno Therapeutics Inc | COM | 300,000 | $12.2M | 4.3% | +100,000+50.0% | Added | History |
| AXSMAxsome Therapeutics, Inc. | COM | 150,000 | $12.1M | 4.2% | −60,000−28.6% | Reduced | History |
| ASNDAscendis Pharma A/S | SPONSORED ADR | 86,721 | $11.8M | 4.1% | +86,721 | New | History |
| PCVXVaxcyte, Inc. | COM | 150,000 | $11.3M | 3.9% | +55,000+57.9% | Added | History |
| CRNXCrinetics Pharmaceuticals, Inc. | COM | 240,000 | $10.7M | 3.7% | +40,000+20.0% | Added | History |
| ROIVRoivant Sciences Ltd. | SHS | 1,000,000 | $10.6M | 3.7% | −300,000−23.1% | Reduced | History |
| CATXPerspective Therapeutics, Inc. | COM NEW | 925,000 | $9.22M | 3.2% | +925,000 | New | History |
| TGTXTG Therapeutics, Inc. | COM | 500,000 | $8.89M | 3.1% | −325,000−39.4% | Reduced | History |
| SRPTSarepta Therapeutics, Inc. | COM | 55,000 | $8.69M | 3.0% | −70,000−56.0% | Reduced | History |
| CGONCG Oncology, Inc. | COM | 260,000 | $8.21M | 2.9% | +185,000+246.7% | Added | History |
| CRBPCorbus Pharmaceuticals Holdings, Inc. | COM NEW | 175,000 | $7.92M | 2.8% | +118,059+207.3% | Added | History |
| VRDNViridian Therapeutics, Inc. | COM | 587,708 | $7.65M | 2.7% | −37,292−6.0% | Reduced | History |
| SNDXSyndax Pharmaceuticals Inc | COM | 350,000 | $7.19M | 2.5% | +200,000+133.3% | Added | History |
| IMVTImmunovant, Inc. | COM | 260,000 | $6.86M | 2.4% | +135,000+108.0% | Added | History |
| TARSTarsus Pharmaceuticals, Inc. | COM | 235,000 | $6.39M | 2.2% | −65,000−21.7% | Reduced | History |
| PHATPhathom Pharmaceuticals, Inc. | COM | 600,000 | $6.18M | 2.2% | +115,000+23.7% | Added | History |
| RZLTRezolute, Inc. | COM NEW | 1,421,501 | $6.11M | 2.1% | +1,421,501 | New | History |
| OLMAOlema Pharmaceuticals, Inc. | COM | 550,000 | $5.95M | 2.1% | +350,000+175.0% | Added | History |
| SYRESpyre Therapeutics, Inc. | COM NEW | 250,237 | $5.88M | 2.0% | +150,237+150.2% | Added | History |
| ALNYAlnylam Pharmaceuticals, Inc. | COM | 22,500 | $5.47M | 1.9% | −37,500−62.5% | Reduced | History |
| APLSApellis Pharmaceuticals, Inc. | COM | 135,000 | $5.18M | 1.8% | +5,000+3.8% | Added | History |
| VKTXViking Therapeutics, Inc. | COM | 95,000 | $5.04M | 1.8% | +21,998+30.1% | Added | History |
| RYTMRhythm Pharmaceuticals, Inc. | COM | 117,388 | $4.82M | 1.7% | −7,612−6.1% | Reduced | History |
| INSMINSMED Inc | COM PAR $.01 | 65,000 | $4.36M | 1.5% | −85,000−56.7% | Reduced | History |
| BPMCBlueprint Medicines Corp | COM | 40,000 | $4.31M | 1.5% | −32,761−45.0% | Reduced | History |
| SVRASavara Inc | COM | 1,050,876 | $4.24M | 1.5% | −549,124−34.3% | Reduced | History |
| TNYATenaya Therapeutics, Inc. | COM | 1,350,000 | $4.18M | 1.5% | +575,000+74.2% | Added | History |
| REPLReplimune Group, Inc. | COM | 450,000 | $4.05M | 1.4% | −200,000−30.8% | Reduced | History |
| ENGNenGene Therapeutics Inc. | COM | 420,331 | $3.96M | 1.4% | +220,331+110.2% | Added | History |
| ACADAcadia Pharmaceuticals Inc | COM | 225,000 | $3.66M | 1.3% | 00.0% | Unchanged | History |
| BBIOBridgeBio Pharma, Inc. | COM | 140,000 | $3.55M | 1.2% | −35,000−20.0% | Reduced | History |
| KRROKorro Bio, Inc. | COM | 100,000 | $3.39M | 1.2% | +100,000 | New | History |
| NUVBNuvation Bio Inc. | COM CL A | 1,150,000 | $3.36M | 1.2% | +1,150,000 | New | History |
| BBOTBridgeBio Oncology Therapeutics, Inc. | CL A ORD SHS | 300,000 | $3.07M | 1.1% | 00.0% | Unchanged | History |
| TSHATaysha Gene Therapies, Inc. | COM SHS | 1,250,000 | $2.80M | 1.0% | +300,000+31.6% | Added | History |
| CABACabaletta Bio, Inc. | COM | 370,899 | $2.77M | 1.0% | −4,101−1.1% | Reduced | History |
| NGNENeurogene Inc. | COM | 70,000 | $2.55M | 0.9% | +45,000+180.0% | Added | History |
| JANXJanux Therapeutics, Inc. | COM | 50,000 | $2.09M | 0.7% | +50,000 | New | History |
| ARVNArvinas, Inc. | COM | 75,000 | $2.00M | 0.7% | +35,000+87.5% | Added | History |
| RGNXREGENXBIO Inc. | COM | 170,000 | $1.99M | 0.7% | +50,000+41.7% | Added | History |
| CYTKCytokinetics Inc | COM NEW | 33,200 | $1.80M | 0.6% | +13,200+66.0% | Added | History |
| ELEVElevation Acquisition Group Inc. | COM | 600,000 | $1.62M | 0.6% | +350,000+140.0% | Added | History |
| KRYSKrystal Biotech, Inc. | COM | 8,500 | $1.56M | 0.5% | −5,500−39.3% | Reduced | History |
| ANNXAnnexon, Inc. | COM | 310,000 | $1.52M | 0.5% | +310,000 | New | History |
| PRQRProQR Therapeutics N.V. | SHS EURO | 900,000 | $1.49M | 0.5% | +900,000 | New | History |
| ATYRaTYR PHARMA INC | COM NEW | 800,000 | $1.25M | 0.4% | +200,000+33.3% | Added | History |
| WVEWave Life Sciences, Inc. | SHS | 200,000 | $998.0K | 0.3% | +200,000 | New | History |
| ARWRArrowhead Pharmaceuticals, Inc. | COM | 35,000 | $909.6K | 0.3% | 00.0% | Unchanged | History |
| SGMTSagimet Biosciences Inc. | COM SER A | 225,000 | $769.5K | 0.3% | 00.0% | Unchanged | History |
| ITCIIntra-Cellular Therapies, Inc. | COM | 10,000 | $684.9K | 0.2% | +10,000 | New | History |
| MGNXMacrogenics Inc | COM | 150,000 | $637.5K | 0.2% | +150,000 | New | History |
| PMVPPMV Pharmaceuticals, Inc. | COM | 375,000 | $607.5K | 0.2% | −300,000−44.4% | Reduced | History |
| PTCTPTC Therapeutics, Inc. | COM | 19,000 | $581.0K | 0.2% | +19,000 | New | History |
| RVNCRevance Therapeutics, Inc. | COM | 225,000 | $578.3K | 0.2% | −225,000−50.0% | Reduced | History |
| NTLAIntellia Therapeutics, Inc. | COM | 25,000 | $559.5K | 0.2% | 00.0% | Unchanged | History |
| ANTXAN2 Therapeutics, Inc. | COM | 219,331 | $471.6K | 0.2% | 00.0% | Unchanged | History |
| CTMXCytomX Therapeutics, Inc. | COM | 300,000 | $366.0K | 0.1% | −300,000−50.0% | Reduced | History |
Options (4)
Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.
Sold out since Q1 2024 (18)
Positions held at the end of Q1 2024 that are gone from this filing.
| Security | Class | Shares in Q1 2024 | Value in Q1 2024 | % of portfolio in Q1 2024 | History |
|---|---|---|---|---|---|
| CATXPerspective Therapeutics, Inc. | COM | 6,000,000 | $7.14M | 2.3% | History |
| JBIOJade Biosciences, Inc. | COM | 225,000 | $6.65M | 2.1% | History |
| GPCRStructure Therapeutics Inc. | SPONSORED ADS | 75,000 | $3.21M | 1.0% | History |
| COGTCogent Biosciences, Inc. | COM | 450,000 | $3.02M | 1.0% | History |
| AQSTAquestive Therapeutics, Inc. | COM | 702,941 | $2.99M | 1.0% | History |
| DCPHDeciphera Pharmaceuticals, Inc. | COM | 176,513 | $2.78M | 0.9% | History |
| GERNGeron Corp | COM | 800,000 | $2.64M | 0.8% | History |
| MRNSMarinus Pharmaceuticals, Inc. | COM NEW | 285,000 | $2.58M | 0.8% | History |
| ALTAltimmune, Inc. | COM NEW | 250,000 | $2.54M | 0.8% | History |
| KALVKalVista Pharmaceuticals, Inc. | COM | 200,000 | $2.37M | 0.8% | History |
| NTRANatera, Inc. | COM | 25,000 | $2.29M | 0.7% | History |
| PTGXProtagonist Therapeutics, Inc | COM | 75,000 | $2.17M | 0.7% | History |
| EYPTEyePoint, Inc. | COM NEW | 90,000 | $1.86M | 0.6% | History |
| MDGLMadrigal Pharmaceuticals, Inc. | COM | 6,500 | $1.74M | 0.6% | History |
| ATXSAstria Therapeutics, Inc. | COM | 115,000 | $1.62M | 0.5% | History |
| LRMRLarimar Therapeutics, Inc. | COM | 210,603 | $1.60M | 0.5% | History |
| RAREUltragenyx Pharmaceutical Inc. | COM | 20,000 | $933.8K | 0.3% | History |
| QUREuniQure N.V. | SHS | 165,000 | $858.0K | 0.3% | History |